OVERVIEW: The Stanley Medical Research Institute (SMRI) now only funds treatment trials for drugs targeting bipolar disorder and schizophrenia.
IP TAKE: SMRI is interested primarily in drug trials that can show results quickly, i.e. within five years.
PROFILE: Created in 1989, the Stanley Medical Research Institute supports the research of drugs aimed at treating bipolar disorder and schizophrenia. It supports research on the causes of, and treatments for, schizophrenia and bipolar disorder.” The institute funds grants through its Treatment Trials and Drug Development Program, which seeks to test the efficacy of drugs that pharmaceutical companies want nothing to do with, including drugs that have lost patent protection, repurposed drugs, and off-label indications.
The majority of SMRI’s grants support the research and development of new treatments, including the repurposing of current drugs used for other illnesses to treat bipolar and schizophrenia. The maximum grant amount is $300,000 for up to three years. Stanley only supports research which can be completed and provide results within five years.
Grant seekers can apply for the grants through the online application. The FAQ section is helpful. One recommendation from the website: keep requests economical — i.e., only ask for the needed amount, not the desired amount.
Application deadlines typically fall around the first of October. The number of funded grants each year varies depending on the number of grantees already supported, but the number of funded trials tends to fall between 50 and 60 at any given time.
- Search for staff contact info and bios in PeopleFinder (paid subscribers only.)